Accord BioPharma, the US speciality division of Intas Pharmaceuticals, has secured approval from the US Food and Drug Administration (FDA) for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab).
DURHAM, N.C., April 29, 2024 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that the U.S. Food and Drug Administration (FDA) has approved HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma.